Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC lessened its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 11.2% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 5,646 shares of the company’s stock after selling 711 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Neurocrine Biosciences were worth $651,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. RFP Financial Group LLC grew its stake in Neurocrine Biosciences by 346.5% during the 1st quarter. RFP Financial Group LLC now owns 192 shares of the company’s stock worth $26,000 after buying an additional 149 shares during the last quarter. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Neurocrine Biosciences in the second quarter valued at approximately $28,000. Innealta Capital LLC purchased a new position in shares of Neurocrine Biosciences during the second quarter worth approximately $30,000. New Covenant Trust Company N.A. acquired a new position in shares of Neurocrine Biosciences in the 1st quarter valued at $32,000. Finally, EdgeRock Capital LLC purchased a new stake in Neurocrine Biosciences in the 2nd quarter valued at $35,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Analyst Upgrades and Downgrades

NBIX has been the topic of several research reports. Raymond James reissued an “outperform” rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. Citigroup boosted their price target on Neurocrine Biosciences from $150.00 to $158.00 and gave the company a “neutral” rating in a research report on Friday, August 2nd. Morgan Stanley upped their price objective on Neurocrine Biosciences from $160.00 to $170.00 and gave the company an “overweight” rating in a research note on Friday, July 12th. Jefferies Financial Group lifted their target price on Neurocrine Biosciences from $177.00 to $189.00 and gave the company a “buy” rating in a research note on Monday, August 19th. Finally, Guggenheim upped their price target on Neurocrine Biosciences from $170.00 to $180.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Five analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $163.91.

Neurocrine Biosciences Trading Down 1.1 %

NBIX stock opened at $123.98 on Friday. The firm has a 50 day moving average of $118.45 and a 200-day moving average of $133.21. The company has a market cap of $12.55 billion, a price-to-earnings ratio of 33.24 and a beta of 0.35. Neurocrine Biosciences, Inc. has a 12-month low of $103.63 and a 12-month high of $157.98.

Insider Buying and Selling

In related news, CFO Matt Abernethy sold 14,100 shares of the business’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $150.38, for a total value of $2,120,358.00. Following the sale, the chief financial officer now directly owns 31,528 shares in the company, valued at $4,741,180.64. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CFO Matt Abernethy sold 14,100 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $150.38, for a total transaction of $2,120,358.00. Following the completion of the transaction, the chief financial officer now directly owns 31,528 shares in the company, valued at $4,741,180.64. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Gary A. Lyons sold 11,570 shares of the stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $150.43, for a total value of $1,740,475.10. Following the sale, the director now owns 119,047 shares in the company, valued at approximately $17,908,240.21. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 47,063 shares of company stock valued at $7,023,330. 4.30% of the stock is owned by insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.